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1. Introduction  
The combination of oxaliplatin or irinotecan with bolus and infusional fluorouracil (FU) and 
folinic acid (FA) is considered the standard regimen for the first-line treatment of metastatic 
colorectal cancer [1–4]. However, this regimen is inconvenient owing to its requirement for 
continuous infusion of FU via vascular access. 
To overcome this drawback, oral fluoropyrimidines such as capecitabine have been used as 
a substitute for infused FU/FA [5], and recent data have shown that capecitabine plus 
oxaliplatin (XELOX) was not inferior to infused FU/FA plus oxaliplatin (known as 
FOLFOX-4 or FUOX) [6, 7]. S-1, a novel dihydropyrimidine dehydrogenase-inhibitory oral 
fluoropyrimidine, has been used widely in patients with gastric cancer. In phase II studies, 
S-1 as a single agent showed an overall response rate (ORR) of 19–40% with tolerable 
toxicities in the first-line treatment of metastatic colorectal cancer [8-10]. 
To explore the possibility of using S-1 to replace the continuous FU infusion of the FOLFOX 
regimen, Korean investigators carried out a phase II clinical trial [11] and Japanese 
investigators performed a phase I/II clinical trial [12] with a regimen of oxaliplatin plus S-1 
(OS) for the first-line treatment of metastatic colorectal cancer, respectively.  
2. Patients and methods 
2.1 Eligibility 
Eligible patients met all of the following criteria: presence of unresectable, metastatic, 
histologically confirmed colorectal cancer; age from 18 to 70 years [11] or from 20 to 74 years 
[12]; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–2 [11] or 0–
1 [12]; estimated life expectancy of more than 3 months; and adequate hematological, renal, 
and hepatic functions. The presence of a unidimensionally measurable lesion was also 
required for the phase II studies. Patients with a previous history of chemotherapy (except 
adjuvant or neoadjuvant chemotherapy not including oxaliplatin or S-1), central nervous 
system metastasis, obvious bowel obstruction, serous gastrointestinal bleeding, or serious 
comorbid conditions were excluded from the study.  
Each patient gave written informed consent before entering the study. The protocol was 
approved by the institutional review board of each center. 
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2.2 Pretreatment evaluations 
Baseline evaluations included medical history, physical examination, ECOG PS, complete 
blood count with differential count, serum chemistry and electrolytes, urine analysis, and 
three-dimensional computed tomography. 
2.3 Treatment scheme 
In phase I part of the Japanese phase I/II study, oxaliplatin was administered at a dose of 
100 mg/m2 (level 1) or 130 mg/m2 (level 2) on day 1, and S-1 (40–60 mg) was given twice 
daily for 2 weeks followed by a 1-week rest [12]. This schedule was repeated every 3 weeks. 
Level 2 was determined to be the recommended dose (RD) for the phase II part of the study. 
In two Japanese and Korean phase II studies, oxaliplatin 130 mg/m2 mixed with 250 mL of 
dextrose solution was administered intravenously over 2 h on day 1, and S-1 40 mg/m2 
[body surface area (BSA) < 1.25 m2, 40 mg; 1.25 ≤ BSA < 1.5, 50 mg; BSA ≥ 1.5, 60 mg] was 
administered orally, twice daily from day 1 to 14, followed by a 7-day rest period [11, 12]. 
The treatment was repeated every 3 weeks until progression of the disease, the development 
of unacceptable toxicity, or consent withdrawal by the patient. 
2.4 Dose modifications 
The dose of a specific agent was adjusted when the cause of toxicity could be distinguished 
[11]. When both agents were believed to have caused the toxicity, the doses of both were 
reduced. Treatment was interrupted in the case of grade 2 or higher toxicity and was not 
resumed until the toxicity resolved or had improved to grade 0 or 1. The dose of oxaliplatin 
was reduced by 25% of the initial dose for related grade 3 toxicities or for the second 
occurrence of same grade 2 toxicity. The dose of S-1 was reduced by 20 mg/day for related 
grade 3 toxicities or for second occurrence of the same grade 2 toxicity. The dose of 
oxaliplatin was reduced by 50% of the initial dose for related grade 4 toxicities or for the 
second occurrence of same grade 3 toxicity. The initial dose of S-1 was reduced by 40 
mg/day for related grade 4 toxicities or for second occurrence of the same grade 3 toxicity. 
No dose increase was allowed. Treatment was discontinued if, despite the dose reduction, 
the same toxicity occurred for a fourth time at grade 2, a third time at grade 3, or a second 
time at grade 4. In addition, if the toxicity had not improved to grade 0 or 1 after 3 weeks to 
allow the continuation of treatment, the patient was removed from the study. 
Dose-limiting toxicity (DLT) was defined as any of the following findings during cycle 1: (1) 
a neutrophil count of less than 500/mm3 for more than 4 days, (2) a platelet count of less 
than 50,000/mm3, (3) diarrhea of grade 3 or more that occurred despite adequate supportive 
therapy, (4) grade 3 or 4 non-hematologic toxicity, excluding nausea, vomiting, anorexia, 
and electrolyte imbalance, or (5) a treatment delay longer than 1 week due to drug-related 
toxicity in the phase I part [12]. If DLT occurred, the dose of oxaliplatin in the subsequent 
course was reduced to 75% of the initial dose and that of S-1 was reduced by one dose level: 
from 80 to 50, 100 to 80, and 120 to 100. S-1 intake was interrupted mid-cycle if there was a 
neutrophil count less than 1,000/mm3, a platelet count less than 75,000/mm3, diarrhea, 
stomatitis, or hand foot syndrome occurred at grade 1 or more, aspartate aminotransferase 
(AST) or alanine aminotransferase (ALT) more than 150 IU/L, total bilirubin more than 1.5 
times the upper limit of normal, or creatinine more than the upper limit of normal. The 
treatment in the subsequent cycle could be resumed if these adverse events resolved within 
3 weeks after the last S-1 treatment. If peripheral neuropathy persisted between courses, the 
next treatment cycle was started at 75% of the previous dose of oxaliplatin. 
www.intechopen.com
 
Oxaliplatin and S-1 for Metastatic Colorectal Cancer 
 
369 
2.5 Response and toxicity evaluation 
The Response Evaluation Criteria in Solid Tumors guidelines [13] were used to evaluate 
tumor responses, and the National Cancer Institute Common Toxicity Criteria (version 3.0) 
were used to assess toxicity. Complete response (CR) was defined as the disappearance of 
all target and nontarget lesions. Partial response (PR) was a 30% or greater decrease in the 
sum of the longest diameter of target lesions, referenced against the baseline sum of the 
longest diameter of target lesions together with stabilization or decrease in size of nontarget 
lesions. Progressive disease (PD) required a 20% or greater increase in the sum of the longest 
diameter of target lesions, an unequivocal increase in the nontarget lesions, or appearance of 
any new lesions. Stable disease (SD) was defined as insufficient shrinkage to qualify for 
partial response and insufficient increase to qualify for progressive disease. Tumor 
responses were evaluated every two cycles [11] or every month [12] by three-dimensional 
computed tomography and were determined by an independent response review 
committee. All partial and complete responses were confirmed not less than 4 weeks after 
the criteria for response were first met. After completion of the study treatment, patients 
were followed up every 2 or 3 months until disease progression or death.  
2.6 Statistical analysis 
The primary aim of these phase II studies was to assess the ORR, and the secondary 
endpoints were safety profile, time to progression (TTP) or progression free survival (PFS), 
overall survival time, and duration of response.  
Simon’s MinMax two-stage design [14] was used to calculate the sample size in the Korean 
study [11]. The first stage required at least seven of 19 patients to have a confirmed 
response, assuming P1 = 0.40, P0 = 0.20,  = 0.05, and  = 0.20, before proceeding to the 
second stage. In the second stage, 20 additional patients were to be entered, to achieve a 
target sample size of 43 assessable patients. Assuming a dropout rate of 10%, 48 patients 
were initially enrolled for the study. 
The sample size was calculated to be at least 28 patients on the assumption of the null 
hypothesis of overall response rate of ≤30% versus the alternative hypothesis of overall 
response rate of > 60%, power 80%, and a 2.5% (one-sided) in the Japanese study [12]. 
The duration of response, TTP, and survival time were estimated using the Kaplan-Meier 
method.  
3. Results 
3.1 Patient characteristics 
Forty-eight patients were enrolled in the Korean study [11]. All patients were assessed for 
safety and survival. Response was evaluated in all patients, except one patient who died due 
to the rupture of an underlying aortic aneurysm after the second cycle but before the 
evaluation, and one patient who had only non-measurable lesions and peritoneal seeding 
with malignant ascites. Patient characteristics are listed in Table 1. There were 25 men, and 
the median age was 56 years (range, 24–70). Twenty-three (48%) had colon cancer, seven 
(15%) had rectosigmoid colon cancer, and 18 (38%) had rectal cancer. Thirty-one patients 
(65%) were diagnosed with metastatic disease. Seventeen patients (35%) had recurrent 
colorectal cancer that relapsed after surgery, with adjuvant chemotherapy or chemo-
radiotherapy. The most common metastatic sites were distant lymph nodes (56%), liver 
(56%), and lung (31%). The median number of metastatic organs was two (range, 1–6).  
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Twenty-nine patients were treated at the RD in the Japanese study [12]. All 29 patients were 
evaluated for toxicity. Efficacy was evaluated in 28 patients. One patient was excluded from 
the analysis of efficacy due to symptoms of brain metastasis suspected to have existed 
before enrolment. There are 20 men, and the median age was 57 years (range 34–71). 
Eighteen (62%) had colon cancer and 11 (38%) had rectal cancer. Four patients had received 
adjuvant oral fluorouracil based therapy.  
 
Characteristic No. of patients (%)   
[ref. 11] 
No. of patients (%) 
[ref. 12] 
Total number of patients  48 (100) 29 (100) 
Gender 
Male 25 (52) 20 (69) 
Female 23 (48) 9 (31) 
Age, years 
Median 56 57 
Range 24−70 34−71 
Eastern Cooperative Oncology Group performance status 
0 39 (81) 26 (90) 
1  8 (17) 3 (10) 
2  1 (2)  
Primary disease site 
Colon 23 (48) 18 (62) 
Rectosigmoid colon 7 (15)  
Rectum 18 (38) 11 (38) 
Surgery and adjuvant therapy 
None 12 (25)  
Resection only 19 (40)* 25 (86) 
Resection + chemotherapy 8 (17) 4 (14) 
Resection + chemotherapy + radiotherapy 9 (19)  
Metastatic sites 
Liver only 9 (19) 10 (35) 
Lung  8 (17) 3 (10) 
Liver and other lesions 18 (38) 10 (35) 
Others 13 (27) 6 (21) 
No. of metastatic sites 
1 19 (40) 15 (52) 
≥2 29 (60) 14 (48) 
*Palliative surgery only.  
Table 1. Patient characteristics 
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3.2 Efficacy  
In total, 413 treatment cycles were administered to 48 patients, with a median of six cycles 
(range, 2–24) per patient in the Korean study [11]. Tumor response data are listed in Table 2. 
There were three CRs, 23 PRs, 17 cases of SD, and three cases of progression. The confirmed 
ORR in the intention-to-treat (ITT) population was 54% (95% CI, 40–68%) and in the per 
protocol (pp) population was 57% (95% CI, 43–71%). The median time to response was 1.5 
months (95% CI, 1.3–1.7), and the median duration of response was 9.3 months (95% CI, 6.5–
12.1). The median duration of follow-up was 21.2 months (95% CI, 17.9–23.6). The median 
TTP in the ITT population was 8.5 months (95% CI, 6.2–10.9). The median survival time was 
27.2 months (95% CI, 20.3–34.0), and the 2-year survival rate in the ITT group was 53%. 
The median number of administered cycles was 6.5 (range: 2–14), and the total number of 
cycles for the 29 patients was 180 in the Japanese study [12]. The ORR was determined by 
the External Review Board. One of the 28 patients given the RD had CR and 13 patients had 
PRs, yielding a response rate of 50% (95% CI, 31–69%). In the 28 patients studied, the 
median PFS was 6.5 months (95% CI, 5.6–10.1). The median overall survival time was not 
reached when 1 year passed since the last patient enrolment, and the 1-year survival rate 
was 79% by the Kaplan–Meier method. 
 
Response* No. of 
patients [ref. 11]
%  (95% CI) No. of 
patients 
[ref. 12] 
% (95% CI) 
Total No. patients 48  29  
Overall response 26 57  (43−71) 14 50  (31−69) 
Complete 3  1  
Partial 23  13  
Stable disease 17  9  
Disease control 43 93 (86−100) 23 82 (68−96) 
Progression 3  5  
Not evaluable 2  1  
Median time to response (months) 1.5 (1.3−1.7)   
Median duration of response (months) 9.3 (6.5−12.1)   
* Response in evaluable patients. 
Table 2. Analysis of response (independent response review committee assessed) 
3.3 Safety 
Safety was assessed in 48 patients based on a total of 413 cycles in the Korean study [11]. The 
adverse events are listed in Table 3. Thrombocytopenia, which developed in 13% of the 
patients, was the most common grade 3/4 adverse event. There was no case of symptomatic 
thrombocytopenia. Neutropenia, observed in 10% of the patients, was the second most 
common grade 3/4 toxicity, and febrile neutropenia developed in one patient. Anemia, 
observed in 6% of the patients, was the third most common grade 3/4 toxicity. Non-
hematologic toxicities were usually mild (mostly grade 1/2) and manageable. The most 
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common non-hematologic toxicities were anorexia, neuropathy, nausea, asthenia, and 
hyperbilirubinemia.  
 
 No. of patients (n = 48) [ref. 11] No. of patients (n = 29) [ref. 12] 
 NCI-CTC grade, version 3 NCI-CTC grade, version 3 
Event All 3 4 3/4 
% 
All 3 4 3/4 
% 
Leukopenia 31 0 0 0 20 0 0 0 
Neutropenia 34 5 0 10 18 4 0 14 
Anemia 49 3 0 6 18 1 0 3 
Thrombocytopenia 28 5 1 13 27 7 1 28 
Anorexia 41 0 0 0 26 0 0 0 
Nausea 35 0 0 0 21 0 0 0 
Vomiting 16 0 0 0 7 0 0 0 
Diarrhea 10 0 0 0 17 1 0 3 
Neuropathy 36 0 0 0 29 0 0 0 
Abnormal AST/ALT 29 0 0 0 n/a    
Hyperbilirubinemia 23 1 0 2 n/a    
Asthenia/ fatigue 27 0 0 0 26 0 0 0 
Allergic reaction  0 0 0 0 1 1 0 3 
NCI-CTC, National Cancer Institute—Common Toxicity Criteria; AST, aspartate aminotransferase; 
ALT, alanine aminotransferase. 
Table 3. Observed adverse events according to number of patients 
The median relative dose intensities (ratio of dose received to dose planned) of oxaliplatin 
and S-1 for all cycles administered were 0.82 (range, 0.46–1.00) and 0.82 (range, 0.52–1.00), 
respectively [11]. The mean relative dose intensities of oxaliplatin and S-1 for all cycles 
administered were 0.79 and 0.83, respectively. The mean relative dose intensities of both 
drugs in each cycle during one to nine treatment cycles are shown in Figure 1. The dose 
reductions and delays during one to nine treatment cycles (total, 311 cycles in 48 patients) 
were as follows. Oxaliplatin was reduced in 37 cycles (12%), primarily because of 
thrombocytopenia (18 cycles), neutropenia (10 cycles), and thrombocytopenia with 
neutropenia (9 cycles). S-1 was reduced in 28 cycles (9%), primarily because of 
thrombocytopenia (14 cycles), neutropenia (8 cycles), and thrombocytopenia with 
neutropenia (6 cycles). Eighty-six cycles (28%) were delayed owing to thrombocytopenia (39 
cycles), neutropenia (34 cycles), thrombocytopenia with neutropenia (10 cycles), and other 
reasons (3 cycles). 
After identification of tolerability at level 2 (130 mg/m2) of oxaliplatin, 29 other patients 
received the RD at 130 mg/m2, including the phase I part patients, to further evaluate the 
tolerability and toxicity of the study regimen [12]. Oxaliplatin could be administered at the 
RD without dose reduction in 57% of 28 patients. At the RD, grade 3 neutropenia was 
observed in four patients (14%), and grade 3 and 4 thrombocytopenia in seven patients 
(24%) and one patient (3%), respectively. The median relative dose intensity was 0.83 for 
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oxaliplatin and 0.75 for S-1 at level 2. The causes of treatment discontinuation at the RD 
were PD in 13 patients (36%), delayed recovery from toxicity such as neutropenia, 
thrombocytopenia, and slight hyperbilirubinemia in 8 patients, discretion of the investigator 
in 2 patients, allergic reaction in 1 patient, and symptomatic deterioration in 1 patient. The 
treatment was discontinued due to prolonged thrombocytopenia in eight patients after a 
median of seven cycles (range, 3–8). No treatment-related death was observed. 
 
 
Fig. 1. Mean relative dose intensities of oxaliplatin and S-1 in each cycle between the 1st and 
9th treatment cycles. 
Sensory neuropathy occurred in all patients [12]. However, no functional impairment was 
observed in this study. The most common non-hematologic toxicities were anorexia, nausea, 
and diarrhea. One patient had grade 3 diarrhea at the RD. Another mild adverse event related 
to treatment was injection site reactions (45%). One patient had severe allergic reactions such 
as skin rash and fever, which are typical platinum-related reactions during the sixth cycle. 
4. Discussion 
The primary outcome of these two studies was the ORR, and the secondary outcomes were 
safety, TTP or PFS, and overall survival time [11, 12]. These studies demonstrated an ORR of 
57% [11] and 50% [12], a median TTP of 8.5 months [11] and PFS of 6.5 months [12], and a 
median survival time of 27.2 months [11] in patients with metastatic colorectal cancer 
treated with the combination of oxaliplatin with S-1. Although these two studies were phase 
II studies, these efficacy results compare favorably to an ORR of 37–54%, a PFS or TTP of 
8.0–9.5 months, and a median survival time of 16.2–20.8 months obtained with infused 
FU/FA and oxaliplatin (FOLFOX or FUFOX) as first-line chemotherapy for metastatic 
colorectal cancer in phase III studies [1, 2, 6, 7, 15-17].  Capecitabine plus oxaliplatin (XELOX 
or CAPOX) is another regimen commonly used in treating colorectal cancer. When 
oxaliplatin 130 mg/m2 (day 1) or 70 mg/m2 (days 1, 8) was administered intravenously, and 
capecitabine 1,000 mg/m2 was administered orally, twice daily on days 1–14, every 3 weeks, 
the ORR, median PFS or TTP, and median overall survival with the XELOX or CAPOX 
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regimen were 37–55%, 6.0-8.9, and 16.8–19.8 months, respectively [5−7, 16, 18–20]. Those 
efficacy data for oxaliplatin combined with infused 5-FU/FA or capecitabine are similar to 
the data for oxaliplatin combined with S-1 in the present studies [11, 12]. 
The median age of the subjects was 56 [11] and 57 years [12], which was relatively younger 
than in other studies, which typically had median ages between 60 and 66 years [6, 7, 15, 16, 
18, 20]. The inclusion criterion for the age of the patients was 18–70 years old [11] and 20–74 
years old [12], while the criterion used in many other studies was age ≥18 years old. This 
might explain the relatively young median age of 56 (range 24–70) years and 57 (range 34–
71) years in Korean and Japanese studies, respectively [11, 12]. 
The treatment was generally well tolerated by most patients. The most common and second 
most common grade 3/4 adverse events were thrombocytopenia (13% [11] and 28% [12] of 
all patients) and neutropenia (10% [11] and 14% [12]), respectively. There was no 
symptomatic thrombocytopenia, and only one patient experienced febrile neutropenia [11]. 
Although peripheral neuropathy was commonly observed (75% [11] and 100% [12]), most 
cases were grade 1 or 2. Hand-foot syndrome was rarely observed in these studies. The 
toxicity profile observed in the present study is different from those of the FOLFOX/FUFOX 
and XELOX/CAPOX regimens. Diarrhea, neutropenia, and neuropathy are major toxicities 
of FOLFOX/FUFOX regimens, and diarrhea, hand-foot syndrome, and neuropathy occur 
most commonly with XELOX/CAPOX regimens [6, 7, 16]. There were few observed grade 
3/4 non-hematologic toxicities, with just one grade 3 hyperbilirubinemia [11], and one grade 
3 diarrhea and one grade 3 allergic reaction [12]. Possible explanations for the reduced 
occurrence of severe non-hematologic toxicities compared to other studies using the XELOX 
regimen include the younger patient population, greater dose reduction or delay, or real 
reduced toxicity of the OS regimen. In contrast, the median age was between 60 and 66 years 
(range, 24–88) in many other studies, while the median age in these studies was 56 and 57 
years (range, 24–71) due to the lower upper limit for patient inclusion. Perhaps younger 
patients can better tolerate the treatment. In addition, strict dose modifications according to 
the toxicities in previous cycles might have reduced the chance of developing more severe 
toxicities in subsequent cycles. Large comparative studies are needed to confirm the more 
favorable toxicity profiles of the OS regimen.  
As expected, the administration of the OS regimen was convenient for the patients. Unlike 
the inconvenient, 2-day, continuous infusion of 5-FU in the FOLFOX regimen, the OS 
regimen requires only a 2-h infusion of oxaliplatin and oral administration of S-1 every 3 
weeks. Thus, the OS regimen was as convenient as the XELOX regimen and required fewer 
clinic visits than the FOLFOX regimen [21]. 
5. Conclusion 
The OS regimen can be an effective, well tolerated, and convenient therapeutic strategy in 
patients with metastatic colorectal cancer. Two comparative clinical trials with the XELOX 
regimen in advanced colorectal cancer are ongoing in Korea.  
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